Kwok F Wong1, Raoul C Reulen1, David L Winter1, Joyeeta Guha1, Miranda M Fidler1, Julie Kelly1, Emma R Lancashire1, Kathryn Pritchard-Jones1, Helen C Jenkinson1, Elaine Sugden1, Gill Levitt1, Clare Frobisher1, Michael M Hawkins2. 1. Kwok F. Wong, Raoul C. Reulen, David L. Winter, Joyeeta Guha, Miranda M. Fidler, Julie Kelly, Emma R. Lancashire, Elaine Sugden, Gill Levitt, Clare Frobisher, and Michael M. Hawkins, University of Birmingham; Helen C. Jenkinson, Birmingham Children's Hospital NHS Foundation Trust, Birmingham; and Kathryn Pritchard-Jones, University College London and Great Ormond Street Hospital for Children, London, United Kingdom. 2. Kwok F. Wong, Raoul C. Reulen, David L. Winter, Joyeeta Guha, Miranda M. Fidler, Julie Kelly, Emma R. Lancashire, Elaine Sugden, Gill Levitt, Clare Frobisher, and Michael M. Hawkins, University of Birmingham; Helen C. Jenkinson, Birmingham Children's Hospital NHS Foundation Trust, Birmingham; and Kathryn Pritchard-Jones, University College London and Great Ormond Street Hospital for Children, London, United Kingdom. m.m.hawkins@bham.ac.uk.
Abstract
PURPOSE: Survivors of Wilms tumor (WT) are at risk for adverse health and social outcomes but risks beyond 30 years from diagnosis remain uncertain. We investigated the risks of adverse outcomes among 5-year survivors of WT, in particular, those between 30 and 50 years from diagnosis. PATIENTS AND METHODS: The British Childhood Cancer Survivor Study includes 1,441 5-year survivors of WT. We investigated cause-specific mortality, risk of subsequent primary neoplasms (SPNs), and, for those who completed a questionnaire, the extent of smoking and drinking, educational achievement, health status, and health service use compared with the general population. RESULTS: Cumulative risk of death from all causes, excluding recurrence, increased substantially from 5.4% to 22.7% at 30 years and 50 years, respectively, after WT diagnosis-75% of excess deaths beyond 30 years from diagnosis were attributable to SPNs (50%) and cardiac diseases (25%). Digestive cancer, most frequently bowel, accounted for 41% of excess cancers beyond 30 years. CONCLUSION: Between 30 and 50 years from diagnosis, survivors of WT are at a substantially increased risk of premature mortality, and 75% of excess deaths were accounted for by SPNs and cardiac diseases. Radiotherapy exposure was a risk factor for both outcomes. The proportion of patients with WT who are exposed to radiotherapy has reduced substantially in recent decades because of initiatives such as the SIOP WT 2001 clinical trial, which sought to reduce late effects; however, the majority of current survivors, who are at least 30 years from diagnosis, received radiotherapy. Surveillance of this group should focus on SPNs, in particular, bowel and breast cancers, and cardiac conditions.
PURPOSE: Survivors of Wilms tumor (WT) are at risk for adverse health and social outcomes but risks beyond 30 years from diagnosis remain uncertain. We investigated the risks of adverse outcomes among 5-year survivors of WT, in particular, those between 30 and 50 years from diagnosis. PATIENTS AND METHODS: The British Childhood Cancer Survivor Study includes 1,441 5-year survivors of WT. We investigated cause-specific mortality, risk of subsequent primary neoplasms (SPNs), and, for those who completed a questionnaire, the extent of smoking and drinking, educational achievement, health status, and health service use compared with the general population. RESULTS: Cumulative risk of death from all causes, excluding recurrence, increased substantially from 5.4% to 22.7% at 30 years and 50 years, respectively, after WT diagnosis-75% of excess deaths beyond 30 years from diagnosis were attributable to SPNs (50%) and cardiac diseases (25%). Digestive cancer, most frequently bowel, accounted for 41% of excess cancers beyond 30 years. CONCLUSION: Between 30 and 50 years from diagnosis, survivors of WT are at a substantially increased risk of premature mortality, and 75% of excess deaths were accounted for by SPNs and cardiac diseases. Radiotherapy exposure was a risk factor for both outcomes. The proportion of patients with WT who are exposed to radiotherapy has reduced substantially in recent decades because of initiatives such as the SIOP WT 2001 clinical trial, which sought to reduce late effects; however, the majority of current survivors, who are at least 30 years from diagnosis, received radiotherapy. Surveillance of this group should focus on SPNs, in particular, bowel and breast cancers, and cardiac conditions.
Authors: Marie A Neu; Alexandra Russo; Arthur Wingerter; Francesca Alt; Johanna Theruvath; Khalifa El Malki; Bettina Kron; Matthias Dittrich; Johannes Lotz; Raimund Stein; Rolf Beetz; Joerg Faber Journal: Pediatr Nephrol Date: 2017-04-28 Impact factor: 3.714
Authors: David I Chu; Abdulla M Ehlayel; Jill P Ginsberg; Kevin E Meyers; Maryjane Benton; Melissa Thomas; Claire Carlson; Thomas F Kolon; Gregory E Tasian; Jason H Greenberg; Susan L Furth; Michelle R Denburg Journal: J Pediatr Date: 2020-12-05 Impact factor: 4.406
Authors: Lisanne Sara Rigter; Frank G J Kallenberg; Barbara Bastiaansen; Theo A M van Os; Floor E van Leeuwen; Monique Esther van Leerdam; Evelien Dekker Journal: BMC Cancer Date: 2016-11-08 Impact factor: 4.430
Authors: Deborah Repullo; Marie Diaz; Stéphane Holbrechts; Maria Gomez-Galdón; Dirk Van Gestel; Ali Bohlok; Gabriel Liberale; Vincent Donckier Journal: World J Surg Oncol Date: 2018-03-07 Impact factor: 2.754
Authors: Nina Streefkerk; Wim J E Tissing; Margriet van der Heiden-van der Loo; Elizabeth A M Lieke Feijen; Eline van Dulmen-den Broeder; Jacqueline J Loonen; Helena J H van der Pal; Cécile M Ronckers; Hanneke M van Santen; Marleen H van den Berg; Renée L Mulder; Joke C Korevaar; Leontine C M Kremer Journal: J Cancer Surviv Date: 2020-05-03 Impact factor: 4.442
Authors: João Victor da Silva Guerra; Bruna Maria de Sá Pereira; Jéssica Gonçalves Vieira da Cruz; Nicole de Miranda Scherer; Carolina Furtado; Rafaela Montalvão de Azevedo; Paulo Sergio Lopes de Oliveira; Paulo Faria; Mariana Boroni; Beatriz de Camargo; Mariana Maschietto Journal: Cells Date: 2019-08-17 Impact factor: 6.600
Authors: Cristian Urla; Steven W Warmann; Monika Sparber-Sauer; Andreas Schuck; Ivo Leuschner; Thomas Klingebiel; Gunnar Blumenstock; Guido Seitz; Ewa Koscielniak; Jörg Fuchs Journal: BMC Cancer Date: 2019-10-14 Impact factor: 4.430